Nanocrystal technology, drug delivery and clinical applications

International Journal of Nanomedicine

Volumn 3, Issue 3, 2008, Pages 295-309

  Junghanns, Jens Uwe A H ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bioavailability enhancement; DissoCubes; Dissolution velocity; Drug nanocrystals; High pressure homogenization; Nanocrystal; Nanopure; Pearl milling; Saturation solubility

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOSPORIN; DERMATOLOGICAL AGENT; DEXAMETHASONE; DRUG CARRIER; FENOFIBRATE; MEGACE ES; MEGESTROL ACETATE; NANOBEAD; NANOCRYSTAL; NANOPARTICLE; NAPROXEN; NPI 32101; NUCRYST; ONDANSETRON; PACLITAXEL; RAPAMYCIN; SEMAPIMOD; SILVER; TACROLIMUS; TH 9402; THERALUX; THYMECTACIN; TRIGLIDE; UNCLASSIFIED DRUG;

ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CHEMOTHERAPY INDUCED EMESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG PACKAGING; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DYSLIPIDEMIA; ENTERITIS; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PRECIPITATION; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STOMACH IRRITATION; STROKE; SUSPENSION;

CRYSTALLIZATION; DRUG CARRIERS; DRUG COMPOUNDING; NANOMEDICINE; NANOSTRUCTURES;

EID: 69749103682     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Anger S. 2005. PhD Thesis. Pharmazeutische Technologie. Berlin, Freie Universität.
2. Bhol KC, Alroy J, Schechter PJ. 2004. Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clin Exp Dermatol, 29:282-7.
3. Bhol KC, Schechter PJ. 2004. Suppressive effects of topical nanocrystalline silver on allergic contact dermatitis in mice. [abstract] Clin Invest Med, 274:196.
4. Bhol KC, Schechter PJ. 2005a. Topical nanocrystalline silver cream inhibits expression of matrix metalloproteinase-9 in animal models of allergic contact dermatitis. [abstract] J Invest Dermatol, 1244:117.
5. Bhol KC, Schechter PJ. 2005b. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Brit J Dermatol, 152:1235-42.
6. Bruno JA, Doty BD, Gustow E, et al. 1992. Method of grinding pharmaceutical substances. US Patent 5518187. USA.
7. Bruno RP, McIlwrick R. 1999. Microfluidizer processor technology for high performance particle size reduction, mixing and dispersion. Eur J Pharm Biopharm, 56:29-36.
8. Bushrab NF, Müller RH. 2003. Nanocrystals of poorly soluble drugs for oral administration. J New Drugs, 5:20-2.
9. Bushrab, N., F. 2005. PhD Thesis (in preparation). Pharmazeutische Technologie. Berlin, Freie Universität.
10. Chong-Hui G, Grant DJW. 2001. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharmacol Sci, 909:1277-87.
11. Cinzia De Vita VC. 2004. Nanostructured hybrid materials from aqueous polymer dispersions. Adv Colloid Interface Sci, 108-109C:167-85.
12. Femia R. 2005. Megestrol acetate nanocrystal: Results of dose-escalating studies under fed and fasting conditions. amfAR's 17th National HIV/ AIDS Update Conference. California, USA.
13. Gassmann P, List M, Schweitzer A, et al. 1994. Hydrosols - alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm, 40:64-72.
14. Grau MJ. 2000. Untersuchungen zur Lösungsgeschwindigkeit, Sättigungslösliclikeit und Stabilität von hochdispersen Arzneistoffsuspensionen. Dissertation. Pharmazeutische Technologie. Berlin, Freie Universität.
15. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharmacol Res, 174:397-404.
16. Investigators, Diabetes Artherosclerosis Intervention Study. 2001. Effect of fenofibrate on progression of coronary - artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet 357:905-10.
17. Junghanns J - UAH. 2006. PhD Thesis (in preparation). Pharmazeutische Technologie. Berlin, Freie Universität.
18. Kanellos M. 2005. Moore says nanoelectronics face tough challenges. CNet News [online]. 9 March. URL: http://www.news.com/ Mooresays-nanoelectronics-face-tough-challenges/ 2100-1006_3-5607422.html?tag=st.nl
19. Kazimierski P. 2005. Nanotechnology for medicine. Alexander von Humboldt Foundation Conference 2005, Piotr: Alexander von Humboldt Foundation.
20. Keck CM, Bushrab NF, Müller RH. 2004. Nanopure® nanocrystals for oral delivery of poorly soluble drugs. Particles, April 20-23, 2002. Orlando, Florida, USA.
21. Kipp JE, Wong JCT, Doty MJ, et al. 2003. Microprecipitation method for preparing submicron suspensions. US Patent 6607784. USA.
22. Kreuter J, Alyautdin RN, Kharkevich DA, et al. 1995. Passage of peptides through the blood - brain barrier with colloidal polymer particles nanoparticles. Brain Res, 6741:171-4.
23. Lee S, Nam K, Kim MS, et al. 2005. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch Pharm Res, 287:866-74.
24. List MA, Sucker H. 1988. Pat No. GB 2200048. Great Britian.
25. Liversidge GG, Conzentino P. 1995. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309-13.
26. Lyczak JB, Schechter PJ. 2005. Nanocrystalline silver inhibits antibiotic-, antiseptic-resistant bacteria. Clin Pharmacol Ther, 77:60.
27. Merisko-Liversidge E, Liversidge GG, Copper ER. 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharma Sci, 18:113-20.
28. Merisko-Liversidge E. 2002. Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. Particles, April 20-23, 2002. Orlando, Florida, USA.
29. Merkle RC. 1999. Biotechnology as a route to nanotechnology. Trends Biotechnol, 17:271-4.
30. Möchwitzer J, Müller RH. 2005. Method for the production of ultrafine submicron nanosuspensions. DE 10 2005 011 786.4. Application, Germany.
31. Möchwitzer J. 2005. PhD Thesis (in preparation). Pharmazeutische Technologie. Freie Universität Berlin.
32. Möchwitzer J, Müller RH. 2004a. From the drug nanocrystal to the final mucoadhesive oral dosage form. International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nürnberg, Germany.
33. Möschwitzer J, Müller RH. 2004b. Nanosuspensions as formulation principle for chemical stabilization of chemically labile drugs. International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nürnberg, Germany.
34. Müller RH, Becker R, Kruss B, et al. 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410. USA.
35. Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 471:3-19.
36. Müller RH, Jacobs C, Kayser O. 2003. DissoCubes - a novel formulation for poorly soluble and poorly bioavailable drugs. In Rathbone MJ, Hadgraft J, Roberts MS (eds). Modified-release drug delivery systems. New York: Marcel Dekker, pp. 135-49.
37. Müller RH, Lück M, Kreuter J. 1998. Arzneistofträgerpartikel für die gewebsspezifische Arzneistoffapplikation. PCT/EP98/06429. Germany.
38. Müller RH, Möchwitzer, JP. 2005. Method and apparatus for the production of ultrafine particles and coating of such particles. DE 10 2005 053 862.2 Application, Germany.
39. Müller RH, Pardeike J, Hommoss A. 2006. Nanoparticles in therapeutics: drug nanocrystals and lipid nanoparticles. MSTI-Congress NanoTrends 2006. Berlin, Germany.
40. Müller RH, Peters K, Becker R, et al. 1995. Nanosuspensions - a novel formulation for the IV administration of poorly soluble drugs. 1st World Meeting of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Budapest.
41. Müller RH. 2002. Nanopure technology for the production of drug nanocrystals and polymeric particles. 4th World Meeting of the Italian Association of Professors and Academic Researchers of Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics and Regulatory Affairs. Florence, Italy.
42. Müller BW, Bleich J. 1996. Production of drug loaded microparticles by the use of supercritical gases with the Aerosol Solvent Extraction System (ASES) process. J Microencapsulation, 132:131-9.
43. NanoCrystal®-Technology-Group 2005. Meeting the challenges of drug delivery. [Brochure] Elan Drug Delivery, Inc.
44. Noyes A, Whitney W. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc, 19:930-4.
45. Pahl MH. 1991. Zerkleinerungstechnik. Cologne: TÜV Rheinland GmbH. Megace ES® PI. 2005. Megace ES tablets [prescribing information]. Par Pharmaceutical Companies, Inc.
46. Sehgal SN. 1998. Rapamune RAPA, rapamycin, sirolimus: mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 531: 335-340.
47. Shackleford DM, Faassen WA, Houwing N, et al. 2003. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther, 3063:925-33.
48. Shimizu S. 2003. Aprepitant Emend ®. New Drug Bulletins: The University of Utah Drug Information Service.
49. Speiser PP. 1998. Poorly soluble drugs: a challenge in drug delivery. In Müller RH, Benita S, Böhm B (eds). Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm Stuttgart: Scientific Publishers, pp. 15-28.
50. Tunick MH, Van Hecken DL, Cooke PH, et al. 2002. Transmission electron microscopy of mozzarella cheeses made from microfluidized milk. J Agric Food Chem, 50:99-103.
51. Velikov K. 2006. Colloidal delivery systems for functional food design. 9th Annual NSTI Nanotechnology Conference and Trade Show, Nanotech 2006. Boston, Massachusetts, USA.
52. Willems L, van der Geest R, de Beule K. 2001. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther, 26:159-61.
53. Witztum JL. 1996. Drugs used in the treatment of hyperdyslipidemias. In Hardman JG, Limbird LE, Monlinoff PB, et al. (eds). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, pp. 875-97.
54. Wua YL, Landisb A, Hettricka E, et al. 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A beagle dog model predicts improved bioavailability and diminished food effect on absorption inhuman. Int J Pharm, 285:135-46.